Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Endocrine 1

Conditions

Peripheral Nervous System Diseases 3Lymphoma 3Lymphoma, Large B-Cell, Diffuse 2Breast Neoplasms 2Wilms Tumor 1Vaso-Occlusive Crises 1Sarcoma 1Prostatic Neoplasms 1Pain 1Neurotoxicity Syndromes 1Neuroectodermal Tumors, Primitive, Peripheral 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Mucositis 1Lymphoma, Non-Hodgkin 1Lymphoma, Extranodal NK-T-Cell 1Leukemia 1Kidney Neoplasms 1Esophagitis 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1Anemia, Sickle Cell 1

Interventions

Prednisone 112Docetaxel 87Leuprolide 79enzalutamide 72Abiraterone Acetate 67bicalutamide 53Goserelin 50acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 42Radiotherapy 39abiraterone 28Magnetic Resonance Spectroscopy 27Gonadotropin-Releasing Hormone 24gallium 68 PSMA-11 23apalutamide 22Androgen Antagonists 22luprolide acetate gel depot 21sipuleucel-T 20Radiosurgery 20Triptorelin Pamoate 18cabazitaxel 17cabozantinib 16Radiotherapy, Intensity-Modulated 16Flutamide 16pembrolizumab 15radium Ra 223 dichloride 14Prednisolone 14Nivolumab 14Dutasteride 14Dexamethasone 14Radiation 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Prostatic Neoplasms × Glutamine × Clear all
NCT01607879 2023-09-22

Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation

Medical College of Wisconsin

Phase 2 Completed
48 enrolled 15 charts
EndocrineGenitourinary

Prostatic Neoplasms, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡